Robinson as chief financial officer. He succeeds Tom Biancardi following the closing of an oversubscribed $75 million Series C financing announced earlier in 2026. With over 15 years’ experience in high-growth public and commercial-stage biotechs, Mr Robinson will support management to accelerate preparations for the potential commercialisation of laru-zova, its lead ocular gene therapy candidate, and to advance its pipeline. Most recently he was CFO and treasurer of Tourmaline Bio, which was acquired by Novartis AG in October 2025. Prior to that, he held financial roles of increasing responsibility at several publicly traded biotechs, including Korro Bio, Jounce Therapeutics and Merrimack Pharmaceuticals.
Beacon Therapeutics announced the appointment on 3 March 2026.
Copyright 2026 Evernow Publishing Ltd.